About Ascenta Therapeutics
Ascenta Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to discovering and developing new medicines to stop cancer. Our core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. We have a compound in Phase IIb clinical trials that inhibit the Bcl-2 family of proteins (Bcl-2, Bcl-xL, Bcl-w, and Mcl-1) and a pipeline that targets IAP (inhibitors of apoptosis proteins) and HDM2 (inhibitor of the p53 tumor suppressor protein). Our development team has broad expertise in oncology and is focused exclusively on addressing the unique obstacles and complex challenges cancer brings to drug development. We are headquartered in Malvern, Pennsylvania in the greater Philadelphia area.
- Industry : Pharma
Product portfolio of Ascenta Therapeutics
News about Ascenta Therapeutics
Here you will find Ascenta Therapeutics
See the theme worlds for related content
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
